980 related articles for article (PubMed ID: 27793510)
21. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.
Evans ME; Feola DJ; Rapp RP
Ann Pharmacother; 1999 Sep; 33(9):960-7. PubMed ID: 10492501
[TBL] [Abstract][Full Text] [Related]
22. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.
Gales AC; Reis AO; Jones RN
J Clin Microbiol; 2001 Jan; 39(1):183-90. PubMed ID: 11136768
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
[TBL] [Abstract][Full Text] [Related]
24. Polymyxin B: similarities to and differences from colistin (polymyxin E).
Kwa A; Kasiakou SK; Tam VH; Falagas ME
Expert Rev Anti Infect Ther; 2007 Oct; 5(5):811-21. PubMed ID: 17914915
[TBL] [Abstract][Full Text] [Related]
25. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics.
Kassamali Z; Jain R; Danziger LH
Int J Infect Dis; 2015 Jan; 30():125-32. PubMed ID: 25461655
[TBL] [Abstract][Full Text] [Related]
26. Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide.
Sader HS; Rhomberg PR; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2015 Dec; 83(4):379-81. PubMed ID: 26415906
[TBL] [Abstract][Full Text] [Related]
27. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09).
Gales AC; Jones RN; Sader HS
J Antimicrob Chemother; 2011 Sep; 66(9):2070-4. PubMed ID: 21715434
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K
Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821
[TBL] [Abstract][Full Text] [Related]
29. Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Polymyxins: Implications for Therapeutic Use.
Nation RL; Forrest A
Adv Exp Med Biol; 2019; 1145():219-249. PubMed ID: 31364081
[TBL] [Abstract][Full Text] [Related]
30. [Shedding light on the use of colistin: still gaps to be filled].
Luque S; Grau S; Berenguer N; Horcajada JP; Sorlí L; Montero MM; Salas E
Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):287-96. PubMed ID: 21440335
[TBL] [Abstract][Full Text] [Related]
31. Rescuing the Last-Line Polymyxins: Achievements and Challenges.
Nang SC; Azad MAK; Velkov T; Zhou QT; Li J
Pharmacol Rev; 2021 Apr; 73(2):679-728. PubMed ID: 33627412
[TBL] [Abstract][Full Text] [Related]
32. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP
Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846
[TBL] [Abstract][Full Text] [Related]
33. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.
Falagas ME; Kasiakou SK
Clin Infect Dis; 2005 May; 40(9):1333-41. PubMed ID: 15825037
[TBL] [Abstract][Full Text] [Related]
34. Colistin in critically ill patients.
Boisson M; Gregoire N; Couet W; Mimoz O
Minerva Anestesiol; 2013 Feb; 79(2):200-8. PubMed ID: 23241733
[TBL] [Abstract][Full Text] [Related]
35. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.
Bergen PJ; Bulman ZP; Saju S; Bulitta JB; Landersdorfer C; Forrest A; Li J; Nation RL; Tsuji BT
Pharmacotherapy; 2015 Jan; 35(1):34-42. PubMed ID: 25630411
[TBL] [Abstract][Full Text] [Related]
36. Colistin: Revival of an Old Polymyxin Antibiotic.
Dijkmans AC; Wilms EB; Kamerling IM; Birkhoff W; Ortiz-Zacarías NV; van Nieuwkoop C; Verbrugh HA; Touw DJ
Ther Drug Monit; 2015 Aug; 37(4):419-27. PubMed ID: 25549206
[TBL] [Abstract][Full Text] [Related]
37. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms.
Yuan Z; Tam VH
Expert Opin Investig Drugs; 2008 May; 17(5):661-8. PubMed ID: 18447592
[TBL] [Abstract][Full Text] [Related]
38. Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.
Zhang X; Guo F; Shao H; Zheng X
J Infect; 2017 Feb; 74(2):118-130. PubMed ID: 27998750
[TBL] [Abstract][Full Text] [Related]
39. Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?
Blaskovich MAT; Pitt ME; Elliott AG; Cooper MA
Expert Rev Anti Infect Ther; 2018 Jun; 16(6):485-499. PubMed ID: 29848132
[TBL] [Abstract][Full Text] [Related]
40. Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations.
Ezadi F; Ardebili A; Mirnejad R
J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30541939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
